Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Date : 08/15/2019 @ 10:11AM
Source : Edgar (US Regulatory)
Stock : Pharmagreen Biotech Inc. (PHBI)
Quote : 0.405  -0.02 (-4.71%) @ 8:59PM

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)



 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one):

OMB APPROVAL

 

OMB Number: 3235-0058
Expires: May 31, 2012
Estimated average burden
hours per response .... 2.50

 

 

 

 

 

 

 

 

[ ] Form 10-K    [             ] Form 20-F    [             ] Form 11-K
[   X] Form 10-Q    [             ] Form 10-D    [             ] Form N-SAR    [             ] Form N-CSR

For Period Ended: June 30, 2019

[             ]

Transition Report on Form 10-K

[             ]

Transition Report on Form 20-F

[             ]

Transition Report on Form 11-K

[             ]

Transition Report on Form 10-Q

[             ]

Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Pharmagreen Biotech Inc.
Full Name of Registrant

N/A
Former Name if Applicable

2987 Blackbear Court, Coquitlam,

British Columbia, V4E 3A2, Canada

,
Address of Principal Executive Office (Street and Number)





PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

x

(a)

The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

 

 

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

 

(c)

The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Pharmagreen Biotech Inc. (the "Company") cannot complete the Form 10-Q within the prescribed time period as management is unable to complete a review of its consolidated financial statements by August 14, 2019. The delay cannot be cured without unreasonable effort or expense. In accordance with Rule 12b-25 under the Securities Exchange Act of 1934, the Company anticipates filing its Form 10-Q no later than five calendar days following the prescribed due date.

PART IV — OTHER INFORMATION

(1)

Name and telephone number of person to contact in regard to this notification


 

Peter Wojcik

702

803-9404

 

(Name)

(Area Code)

(Telephone Number)


(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).

[ x ] Yes [             ] No

 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?

[             ] Yes [ x ] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.






Pharmagreen Biotech Inc.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 15, 2019

By:

/s/ Peter Wojcik

 

 

Peter Wojcik

 

Title:

President, Director






Pharmagreen Biotech Inc. (USOTC:PHBI)
Historical Stock Chart

1 Year : From Jan 2019 to Jan 2020

Click Here for more Pharmagreen Biotech Inc. Charts.

Pharmagreen Biotech Inc. (USOTC:PHBI)
Intraday Stock Chart

Today : Tuesday 28 January 2020

Click Here for more Pharmagreen Biotech Inc. Charts.

Latest PHBI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.